Delving into the Latest Updates on Parecoxib Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide, parecoxib, Parecoxib sodium (USAN)

+ [8]

Target

COX-2

Action

inhibitors

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Pain, Postoperative

Inactive Indication

ColicRenal Colic

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Australia Pty Ltd.Pfizer Europe MA EEIG

Pfizer Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (22 Mar 2002),

Pain, Postoperative

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H18N2NaO4S

InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N

CAS Registry198470-85-8

Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

Start Date01 May 2026

Sponsor / Collaborator

Armed Forces Hospital

ChiCTR2500095107

/ SuspendedNot ApplicableIIT

Effect of esketamine combined with parecoxib sodium on postoperative analgesia and inflammatory response in patients with thoracoscopic pulmonary resection

Start Date05 Jan 2025

Sponsor / Collaborator-

NCT06579274

/ Not yet recruitingPhase 2IIT

A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage

Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.

Start Date01 Jan 2025

Sponsor / Collaborator

St. Anne's University Hospital Brno

[+1]

100 Clinical Results associated with Parecoxib Sodium

Login to view more data

100 Translational Medicine associated with Parecoxib Sodium

Login to view more data

100 Patents (Medical) associated with Parecoxib Sodium

Login to view more data

1,316

Literatures (Medical) associated with Parecoxib Sodium

01 May 2025·ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE

The Laparoscopic Right-lower Quadrant Approach for the Treatment of Right-sided Colon Cancer Offers Advantages Such as Shorter Surgical Time and Less Blood Loss.

Article

Author: Chen, Peng ; Zhang, Chuanxin ; Zhang, Xu ; Xu, Anqi ; Zheng, Xin

Objective:

This study aims to compare the therapeutic efficacy of laparoscopic right-lower quadrant and midline approaches for the treatment of right-sided colon cancer and evaluate the analgesic effect of parecoxib sodium.

Methods:

Sixty patients with right-sided colon cancer admitted to Hospital of Lin 'an District between January 2019 and November 2022 were selected. They were divided into the study group A (n=30) with a right-lower quadrant approach and the study group B (n=30) with a midline approach. All patients received parecoxib sodium. Surgical time, blood loss, postoperative complications, and other relevant indicators were recorded and compared between the two groups. Additionally, a control group of 60 right-sided colon cancer patients who underwent conventional non-exclusive analgesic laparoscopic surgery during the same period was included to compare the analgesic effects between the study and control groups.

Results:

The surgical time (RR = 0.608, 95%CI 0.51, 1.53, P = .042), blood loss (RR = 0.798, 95%CI 0.52, 1.02, P < .001), time for bowel function recovery (RR = 0.808, 95%CI 0.50, 1.77, P = .007), and length of hospital stay (RR = 0.766, 95%CI 0.56, 1.72, P =.052) were significantly lower in group A than in group B, while the number of lymph node dissections was higher in group A (RR = 0.803, 95%CI 0.62, 1.52, P = .047). The postoperative levels of tumor-specific growth factor (TSGF) (RR = 0.710, 95%CI 0.50, 1.55, P < .001) and carcinoembryonic antigen (CEA) (RR = 0.803, 95%CI 0.62, 1.52, P < .001) were significantly decreased in both groups A and B, with no significant difference between the groups (P > .05). The incidence of complications in group A was significantly lower than in group B (RR = 0.167, 95%CI 0.17, 0.63, P = .044). The VAS scores of the study group at 2/4/6/8 hours postoperatively were significantly lower than those of the control group (RR = 0.702, 95%CI 0.52, 1.62, P < .001). The SF-36 scores of the study group were significantly higher than those of the control group (RR = 0.753, 95%CI 0.56, 1.82, P < .001).

Conclusions:

The Laparoscopic right-lower quadrant approach for the treatment of right-sided colon cancer offers advantages such as shorter surgical time and less blood loss. It demonstrates significant clinical efficacy and reduces the incidence of postoperative complications. Parecoxib sodium enhances postoperative analgesic effect, effectively alleviating patient pain, promoting recovery, and improving quality of life. It is worth promoting in clinical practice.

01 Mar 2025·JOURNAL OF ARTHROPLASTY

Non-Opioid Analgesics for Postoperative Pain Management Following Total Joint Arthroplasty: A Systematic Review and Meta-Analysis

Article

Author: Slawaska-Eng, David ; Al-Rubaie, Sammy ; Cohen, Dan ; Syed, Imran M ; Khanna, Vickas ; Al-Besher, Muhammad

BACKGROUND:

Hip and knee arthroplasty are a fundamental part of modern orthopaedic practice. These procedures often require extensive postoperative analgesia, including opiate painkillers that are frequently associated with adverse side effects and risk of abuse. This review, therefore, investigated how postoperative administration of nonopioid coanalgesics (e.g., parecoxib, pregabalin) can affect postoperative pain scores and opioid use.

METHODS:

A systematic search of OVID, Embase, Medline, and PubMed was conducted, and studies were filtered to trials of patients undergoing arthroplasty who received nonopioid analgesia. Several meta-analyses were conducted to investigate the effects of various medications and classes at multiple postoperative time points on pain scores and opioid use. Standardized mean differences were conducted for analyses involving more than one measure of pain. There were 28 analyses included in the final review.

RESULTS:

On average, nonsteroidal anti-inflammatory drugs (NSAIDs) and gabapentinoids reduced between 9.30 and 10.89 mg, respectively of intravenous morphine in a 24-hour period. Reductions were also observed at various time points for NSAIDs, gabapentinoids, parecoxib, and pregabalin. Nonopioid coanalgesia improved pain at rest for various time points, including NSAIDs at postoperative day (POD) 1 and PODs 3 and 5. Parecoxib and corticosteroids were protective at POD 3. Pain during movement was significantly reduced by NSAIDs at 6 hours, POD 1, 2, and 3, with parecoxib demonstrating similar benefits at POD 1 and POD 2 to 3.

CONCLUSIONS:

This review found that postoperative administration of nonopioid coanalgesia may alleviate the need for opioids and have modest protective effects on postoperative pain. The effects of these analgesics, however, may be clinically nonmeaningful for reducing pain. These results may further implicate a need to implement nonopioid coanalgesia in postoperative patient care. Future research may include an updated investigation of this research question as more medication granular research becomes available.

01 Mar 2025·MOLECULAR IMMUNOLOGY

Synergistic therapeutic effect of parecoxib and ilomastat combination in osteoarthritis via inhibition of IL-17/PI3K/AKT/NF-κB activity

Article

Author: Zhao, Yuhao ; Song, Zhengdong ; Feng, Xiaofei ; Ma, Yao ; Zhao, Zhenrui ; Lin, Li ; Wang, Wenji

BACKGROUND:

Osteoarthritis is a degenerative disease, and current drug treatment is to give nonsteroidal anti-inflammatory drugs to relieve symptoms. The anti-inflammatory ability of parecoxib and ilomastat has been confirmed, but the synergistic effect of combined administration in osteoarthritis has not been clear.

METHODS:

Mouse primary chondrocytes stimulated with IL-1β were cultured. The expression levels of inflammatory cytokines and matrix metalloproteinases were investigated by western blotting, quantitative real-time polymerase chain reaction and ELISA. The effects of parecoxib and ilomastat on chondrocyte apoptosis were evaluated by flow cytometry. In addition, the rat model of osteoarthritis was established by meniscal instability, and the morphological changes of cartilage and the expression levels of related molecules were monitored using Safranin O-Fast green and immunohistochemical staining after intra-articular injection of parecoxib, ilomastat, and the combination of the two.

RESULTS:

In vitro experiments showed that the combined administration of parecoxib and ilomastat more effectively inhibited the expression of proinflammatory factors and matrix metalloproteinases compared with single drug administration. The combined drug treatment could more effectively inhibit IL-1β-induced chondrocyte apoptosis. The combined drug treatment alleviated the progression of osteoarthritis by inhibiting the IL-17/PI3K/AKT/NF-κB pathway. In addition, in vivo experiments showed that the combined administration could improve the further deterioration of the osteoarthritis rat model.

CONCLUSIONS:

The combined administration of parecoxib and ilomastat to inhibit IL-17/PI3K/AKT/NF-κB transduction is beneficial to reduce the infiltration of inflammatory factors and matrix metalloproteinases in osteoarthritis.

1

News (Medical) associated with Parecoxib Sodium

11 Sep 2023

·www.pharmaindustrial-india.com

Gufic Biosciences Ltd Receives TGA Australia and ANVISA Brazil Approval for Parecoxib 40mg Injection

Gufic Biosciences Limited (Gufic) have received approval from the Therapeutic Group Administration (TGA), Australia and the National Health Surveillance Agency (ANVISA), Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection, a selective COX-2 inhibitor, which shall be used for short-term treatment of acute pain and post-operative pain in adult patients. Gufic has been persistently committed to saving and improving lives of patients across the globe with its continuous efforts through the international regulatory agencies to bring novel molecules for the mankind. Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management. Selective COX-2 inhibitors were developed to avoid the gastrointestinal side effects related to COX-1 inhibitors. Parecoxib is a prodrug of a sulphonamide based COX-2 inhibitor, Valdecoxib, a potent anti-inflammatory and analgesic drug. Following a single Intravenous (IV) or Intramuscular (IM) dose, Parecoxib is rapidly converted to Valdecoxib by enzymatic hydrolysis in Liver. Parecoxib's first perceptible analgesic effect occurs within seven to thirteen minutes, with a peak effect within two hours following administration of single dose of 40mg injection by IV or IM route. Parecoxib has more potent synergistic effects when combined with morphine than other COX-2 NSAIDs and reduces the amount of opioid needed for adequate analgesia. This overall reduction in opioid drug improves the safety margin of the analgesic regime and provides better analgesic coverage.

Drug Approval

100 Deals associated with Parecoxib Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03717	Parecoxib Sodium	M01AH04	DB08439

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	European Union	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Iceland	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Liechtenstein	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Norway	Pfizer Europe MA EEIG	22 Mar 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	Australia	Pfizer Inc.	01 Apr 2003
Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002
Renal Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ILCA2020	Not Applicable	Hepatocellular Carcinoma	-	Parecoxib sodium + TAP block	elmvueypaz(vtzfnptdrh) = No significant differences were found between the two groups related to adverse events riwckaxsun (xigvjqgetn ) View more	Positive	13 Sep 2020
ILCA2020	Phase 3	Hepatocellular Carcinoma	80	Parecoxib sodium 40 mg	rogqdugdcn(wryfwyxiad) = kfwoymvhup xclhajxzuy (nhzqkykxwa, 9.8 - 28.2) View more	Positive	13 Sep 2020
				Placebo	rogqdugdcn(wryfwyxiad) = jxrrdtzdcw xclhajxzuy (nhzqkykxwa, 8.1 - 19.9) View more
NCT01566669 (PCEA, Pubmed \| PLoS One)	Not Applicable	-	240	Parecoxib	blxjyolstv(hbnqgoilkh) = vqcvnxyddf ixhigbbbdl (uspbtjyrbl ) View more	Positive	01 Jan 2016
				Placebo	blxjyolstv(hbnqgoilkh) = hztdxzryoz ixhigbbbdl (uspbtjyrbl ) View more
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) Manual	Phase 4	Hemorrhage \| Analgesia	105	Morphine+parecoxib	rvrvqdsoeg(irdjtwipnz) = emhdkebtcl tdgbwflqtt (wqxxxsjyeg, 24.1) View more	Positive	09 Mar 2015
				Morphine+Placebo	rvrvqdsoeg(irdjtwipnz) = knsaibsibu tdgbwflqtt (wqxxxsjyeg, 28) View more
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	tryxtjizkv(sjbylahlvd) = lembexesmy ofycauzqdj (ipyumozdqd, 3.35) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	tryxtjizkv(sjbylahlvd) = qfmkvjasfo ofycauzqdj (ipyumozdqd, 3.46) View more
NCT00346268 (PROSTATECTOMY, CTgov)	Phase 4	Pain, Postoperative	105	Parecoxib+Morphine (Parecoxib and Morphine)	xcwtrvsyfb(ofygxomftq) = zjokrcqwnx zjdkpavexx (blxoyowhpv, 16.16) View more	-	28 Oct 2011
				Placebo+Morphine (Placebo and Morphine)	xcwtrvsyfb(ofygxomftq) = puitzrapkw zjdkpavexx (blxoyowhpv, 19.99) View more
NCT00455117 (Pubmed \| Br J Anaesth)	Phase 4	Pain, Postoperative	-	Parecoxib 40 mg	uhghifscef(yyfmwfayix) = pyzntvkdcb opqbnrsbzh (cjmscvvplp )	Negative	01 Sep 2011
				Placebo	uhghifscef(yyfmwfayix) = sqnvkpucgf opqbnrsbzh (cjmscvvplp )